3,452 Shares in Waters Corporation $WAT Bought by Folger Nolan Fleming Douglas Capital Management Inc.

Folger Nolan Fleming Douglas Capital Management Inc. bought a new stake in shares of Waters Corporation (NYSE:WAT) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,452 shares of the medical instruments supplier’s stock, valued at approximately $1,028,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in WAT. SevenBridge Financial Group LLC raised its stake in Waters by 47.9% in the first quarter. SevenBridge Financial Group LLC now owns 1,479 shares of the medical instruments supplier’s stock valued at $440,000 after buying an additional 479 shares during the last quarter. Capital Investment Counsel LLC grew its stake in shares of Waters by 0.3% during the first quarter. Capital Investment Counsel LLC now owns 14,199 shares of the medical instruments supplier’s stock worth $4,228,000 after acquiring an additional 48 shares during the last quarter. McMillan Office Inc. grew its stake in shares of Waters by 43.6% during the first quarter. McMillan Office Inc. now owns 1,410 shares of the medical instruments supplier’s stock worth $420,000 after acquiring an additional 428 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ increased its holdings in shares of Waters by 62.3% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 31,874 shares of the medical instruments supplier’s stock valued at $9,492,000 after acquiring an additional 12,231 shares in the last quarter. Finally, North Star Investment Management Corp. increased its holdings in shares of Waters by 10,200.0% during the first quarter. North Star Investment Management Corp. now owns 103 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 102 shares in the last quarter. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on WAT shares. Wolfe Research started coverage on shares of Waters in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 target price for the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $350.00 target price on shares of Waters in a research report on Thursday, May 7th. The Goldman Sachs Group raised shares of Waters to a “strong-buy” rating in a report on Wednesday, April 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Waters in a report on Monday, April 20th. Finally, Evercore raised shares of Waters from an “in-line” rating to an “outperform” rating and set a $350.00 price objective on the stock in a report on Monday, April 6th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $396.68.

Waters Price Performance

Shares of NYSE WAT opened at $369.65 on Tuesday. Waters Corporation has a 52 week low of $275.05 and a 52 week high of $414.15. The business’s 50 day moving average price is $347.97 and its 200 day moving average price is $347.09. The company has a quick ratio of 1.13, a current ratio of 1.79 and a debt-to-equity ratio of 0.32. The firm has a market cap of $36.30 billion, a P/E ratio of 46.97, a P/E/G ratio of 2.26 and a beta of 1.21.

Waters (NYSE:WAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the consensus estimate of $2.31 by $0.39. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. The business’s quarterly revenue was up 91.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. On average, sell-side analysts expect that Waters Corporation will post 14.51 earnings per share for the current year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.